Riverside Clinical Laboratory INC

Riverside Clinical Laboratory INC was paid $34K by Medicaid between Apr 2022 and Oct 2024, across 24 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 55% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#379 of 561

Median peer was paid$222K

This provider vs. median0.2×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2022	489	$21K
2023	353	$3K
2024incomplete	7,536	$10K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	55%	309	172	$19K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	26%	1,111	1,007	$9K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	6.6%	1,133	1,078	$2K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	4.7%	121	98	$2K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	2.0%	59	44	$673.50
87631		1.1%	32	14	$362.76
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	1.0%	350	343	$358.62
87481		<1%	917	893	$199.30
87500		<1%	920	896	$199.30
87640		<1%	918	894	$199.30
87641		<1%	904	881	$197.31
87653		<1%	944	918	$195.03

12 more codes

80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	115	$46.55
87101		<1%	197	$37.02
87634		0%	40	$0.00
G0659	Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes	0%	16	$0.00
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	0%	40	$0.00
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	0%	12	$0.00
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	0%	40	$0.00
87532		0%	40	$0.00
86317		0%	40	$0.00
87498		0%	40	$0.00
87486		0%	40	$0.00
87581		0%	40	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMOHAMMED, HYDER (PRESIDENT)